Combination Therapy Holds Promise for Newly Diagnosed Systemic AL Amyloidosis Patients


Updated research regarding the ANDROMEDA study presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, indicated the efficacy of subcutaneous daratumumab (DARA SC) and cyclophosphamide, bortezomib, and dexamethasone (CyBorD) as a combination therapy in newly diagnosed light chain (AL) amyloidosis patients.
 
Daratumumab is a previously approved CD38-directed cytolytic antibody agent for the treatment of multiple myeloma via infusion. CyBorD is a 3-drug combination. Cyclophosphamide is an immunosuppressive and chemotherapy, bortezomib is a potent first-in-class proteasome inhibitor, and dexamethasone is a corticosteroid. All drugs have been previously approved independently or with other combinations.
 
Combination Therapy Holds Promise For Newly Diagnosed Systemic AL Amyloidosis Patients